Allergy Therapeutics (LON:AGY) Shares Down 14.3% – Here’s Why

Allergy Therapeutics plc (LON:AGY) shares traded down 14.3% on Tuesday . The company traded as low as GBX 9 and last traded at GBX 9. 308,884 shares were traded during mid-day trading, an increase of 7% from the average session volume of 288,162 shares. The stock had previously closed at GBX 10.50.

Allergy Therapeutics Trading Down 4.8%

The firm has a market capitalization of £633.25 million, a PE ratio of -11.90, a P/E/G ratio of -30.70 and a beta of 0.83. The business has a 50 day moving average price of GBX 11.10 and a 200-day moving average price of GBX 9.97. The company has a current ratio of 1.28, a quick ratio of 1.48 and a debt-to-equity ratio of -213.13.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings results on Monday, February 16th. The company reported GBX (0.84) earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 72.91% and a positive return on equity of 227.10%. Analysts expect that Allergy Therapeutics plc will post -2.56 earnings per share for the current year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.